Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

Data taken from [36]. Polymyalgia rheumatica (PMR) is the second most common autoimmune rheumatic disorder; giant cell arteritis (GCA) is the most frequent vasculitis in the elderly. PMR patients ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release ...

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are linked conditions that occur in the elderly. GCA is a vasculitis of large- and medium-sized vessels causing critical ischemia.

aSection of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, ...

Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR). According to GlobalData, Phase II drugs for Polymyalgia Rheumatica (PMR) have ...

Among patients with giant cell arteritis, only 21.2% achieved sustained drug-free remission over a median follow-up period of 3 years. Sustained drug-free remission (SDFR) is rare in giant cell ...

but longer follow-up studies are required to investigate the possible occurrence of late flares or events of giant cell arteritis. In conclusion, the BACHELOR trial shows that baricitinib is effective ...